Revenue From License Agreement was Korsana Biosciences’s largest product and service line in fiscal 2024, bringing in $1.75M of $2.00M (88%).
| Product and Service | FY 2024 |
|---|---|
| Revenue From License Agreement | $1.75M |
| Option To License Revenue | $250.00K |
| Total | $2.00M |
Korsana Biosciences brought in $2.00M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. Revenue From License Agreement was the largest at $1.75M (87.5%), ahead of Option To License Revenue at $250.00K (12.5%).
Korsana Biosciences (KRSA) reports its revenue by product and service. In fiscal 2024, Revenue From License Agreement was its largest product and service line, bringing in $1.75M (87.5% of the total), followed by Option To License Revenue at $250.00K (12.5%).
Revenue From License Agreement was Korsana Biosciences' largest product and service line in fiscal 2024, bringing in $1.75M, or 87.5% of the $2.00M total across its two product and service lines.
Every figure comes from Korsana Biosciences' annual financial filings, as reported. Each line keeps the name Korsana Biosciences gives it, and years follow its fiscal calendar.
Korsana Biosciences' revenue by product and service goes back to fiscal 2024, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.